Phase 2 Evidence and Impact Analysis
I am analyzing each article independently, applying conservative scoring caps where appropriate (non-human studies ≤5 on Clinical Relevance; low classification_confidence = conservative scores; preprints cannot exceed 7 on Evidence Strength). Articles with triage scores ≤4 or classification_confidence = low receive streamlined treatment.
Article-by-Article Scoring (Top Articles by Triage Score)
Article 1 — Xu et al. — Giant cell tumor of bone, novel H3F3A mutation (PMID 42743822) Cohort/Observational, peer-reviewed, triage score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Novel H3F3A insertion variant is genuinely new; however, a single cohort with no functional data limits novelty claim |
| Clinical Relevance | 5 | Differential diagnosis of bone lesions is clinically meaningful; no treatment change yet possible from this alone |
| Population Reach | 3 | Giant cell tumor of bone is relatively uncommon; limited population affected |
| Implementation Speed | 3 | Multicenter and functional studies explicitly needed before any translation |
| Evidence Strength | 4 | Single-center cohort, abstract only; no functional validation |
Key quantitative result: Novel p.V36_K37insL variant identified; no effect size or survival data extractable from abstract. External validation: None; authors call for multicenter studies. Main limitation: No functional characterization; single center; abstract only. Equity implications: Bone tumors may be underdiagnosed in resource-limited settings; no specific equity analysis. Evidence Maturity Revision: Exploratory (downgraded from "Validated" — a single cohort identifying a variant without functional data does not meet Validated threshold).
Article 2 — Yu et al. — Cadonilimab vs PD-(L)1 in front-line gastric cancer (network meta-analysis) (PMID 42744764) Network meta-analysis (inferred RCT synthesis), peer-reviewed, triage score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First systematic synthesis comparing cadonilimab (PD-1/CTLA-4 bispecific) to standard PD-(L)1 therapy in GC; addresses FDA ODAC-identified gap in low PD-L1 patients |
| Clinical Relevance | 8 | Directly addresses a clinician decision point: which ICI is best for low PD-L1 GC? Practice-relevant comparison |
| Population Reach | 7 | Gastric/GEJ cancer is among the top global cancer killers; HER2-negative disease is the majority subtype |
| Implementation Speed | 5 | Cadonilimab already approved (China); broader adoption depends on regulatory decisions elsewhere; network meta-analysis may accelerate guideline update |
| Evidence Strength | 6 | Network meta-analysis of RCTs is methodologically sound but indirect comparisons carry uncertainty; abstract only, no effect sizes visible |
Key quantitative result: Not extractable from abstract; selection of appropriate ICI shown to affect outcomes (specific HR/OS data not available). External validation: Synthesis of existing RCT data; no new prospective validation. Main limitation: Network meta-analysis relies on indirect comparisons; heterogeneity across trials; abstract-only. Equity implications: GC disproportionately affects East Asian populations; cadonilimab availability currently limited to China; global access inequity is real. Evidence Maturity Revision: Potentially Practice-Changing — confirmed. Network meta-analysis is the appropriate design for this question given direct head-to-head data are unavailable.
Article 3 — Shah et al. — Real-world post-ICI treatment in metastatic ccRCC (PMID 42742451) Cohort/Observational, peer-reviewed, triage score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Real-world characterization of post-ICI RCC landscape (2018–2023) fills genuine evidence gap; not mechanistically novel |
| Clinical Relevance | 7 | Directly informs second-line treatment decisions; documents survival outcomes in poorly characterized setting |
| Population Reach | 5 | RCC affects ~430,000 globally/year; metastatic subset is smaller but high mortality; unmet need is significant |
| Implementation Speed | 5 | Documents current landscape rather than offering new therapy; useful for guideline development now |
| Evidence Strength | 5 | Real-world cohort with selection bias risk; abstract only; no sample size or effect estimates visible |
Key quantitative result: Not extractable from abstract; confirms high unmet need with poor outcomes post-ICI. External validation: Single database/registry analysis; not externally validated. Main limitation: Observational design; selection bias; confounding by indication; abstract only. Equity implications: Real-world data may reflect access inequities in novel therapies post-ICI; populations without access to clinical trials especially relevant. Evidence Maturity Revision: Validated (confirmed for real-world characterization purposes, though not for any specific treatment recommendation).
Article 4 — Resto-Santos et al. — AML with inv(3)/t(3;3), single-center retrospective (PMID 42743820) Cohort/Observational, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | MECOM-rearranged AML is well-described as high-risk; retrospective outcomes data adds incremental knowledge |
| Clinical Relevance | 6 | Relevant to hematologists managing a rare, very poor-prognosis AML subtype; reinforces need for novel strategies |
| Population Reach | 3 | inv(3)/t(3;3) AML represents ~1–2% of all AML cases — very rare population |
| Implementation Speed | 3 | Single-center retrospective; needs multicenter validation before influencing practice |
| Evidence Strength | 4 | Single-center, retrospective cohort; abstract only; no sample size visible |
Evidence Maturity Revision: Exploratory (downgraded from "Validated" — single-center retrospective on a rare subtype is Exploratory).
Article 5 — Cao et al. — Robotic assistance in total hip arthroplasty, meta-analysis (PMID 42742817) Meta-analysis, peer-reviewed, triage score: 8
Note: This article was matched to "Hematologic malignancies" by the triage agent — this is a clear topic mismatch. The article is about orthopedic surgery and has no relevance to this watchlist. Scoring is adjusted accordingly; it will not rank highly.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Robotic-assisted THA literature is mature; this adds quantitative synthesis but no fundamental novelty |
| Clinical Relevance | 5 | Relevant to orthopedic surgeons; not relevant to this watchlist's focus |
| Population Reach | 6 | THA is one of the most common elective procedures globally |
| Implementation Speed | 5 | Robotic systems already in use; findings could accelerate/narrow adoption |
| Evidence Strength | 6 | Meta-analysis methodology sound, but authors acknowledge nonrandomized study dominance and heterogeneity |
Evidence Maturity Revision: Validated (within orthopedic domain). Out of scope for this watchlist — will not rank in top tier.
Article 6 — Lyu et al. — Chidamide + venetoclax post-transplant maintenance in AML/MDS (PMID 42742782) Journal Article (unspecified design), peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | CHI+VEN combination as post-allo-HSCT maintenance is a genuinely novel strategy; venetoclax post-transplant is an emerging area |
| Clinical Relevance | 7 | Directly addresses the leading cause of allo-HSCT failure (relapse); targets patients with high unmet need |
| Population Reach | 4 | High-risk AML/MDS post-transplant is a relatively small but extremely high-mortality population |
| Implementation Speed | 5 | Both drugs are available; regimen could be piloted in trials relatively quickly; but needs RCT confirmation |
| Evidence Strength | 4 | Study design unspecified; likely small single-arm or retrospective series; abstract only |
Evidence Maturity Revision: Exploratory (confirmed — "encouraging efficacy" language and unspecified design = hypothesis-generating).
Article 7 — Ataca et al. — Early-onset colorectal cancer screening, systematic review (PMID 42743896) Review, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | EOCRC screening gap is a recognized and growing concern; this synthesizes existing literature without new data |
| Clinical Relevance | 7 | Directly relevant to screening age policy and clinical practice; rising EOCRC incidence is an urgent issue |
| Population Reach | 8 | Adults under 50 with CRC risk is a large and growing group globally; policy implications are substantial |
| Implementation Speed | 6 | Lowering screening age thresholds is already in progress in some countries; recommendations could be adopted relatively quickly |
| Evidence Strength | 4 | Narrative/systematic review without original data; abstract only; no quantitative pooling apparent |
Evidence Maturity Revision: Exploratory (confirmed — review calling for individualized risk assessment, not providing new validated evidence).
Article 8 — Vogel & Kelley — Systemic therapy for HCC: doublets, triplets and beyond (review) (PMID 42744526) Review, J Hepatol, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Review of existing landscape; J Hepatol is high-impact and this likely reflects current consensus/frontier |
| Clinical Relevance | 7 | HCC treatment is evolving rapidly; this review in J Hepatol will influence clinical practice |
| Population Reach | 7 | HCC is the most common primary liver cancer globally; ~900,000 new cases/year |
| Implementation Speed | 5 | Review may accelerate guideline updates; no new intervention |
| Evidence Strength | 4 | Review article; no original data |
Evidence Maturity Revision: Exploratory (confirmed — summarizes emerging strategies, not established practice).
Article 9 — Surendran et al. — Circulating free bacterial DNA as biomarker in pancreatic cancer (PMID 42743886) Cohort/Observational, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Circulating free bacterial DNA (cfbDNA) as a therapy response biomarker in PDAC is genuinely novel; distinct from ctDNA |
| Clinical Relevance | 6 | Pancreatic cancer monitoring is an area of high unmet need; promising but prospective validation required |
| Population Reach | 5 | PDAC: ~500,000 new cases/year globally; high mortality |
| Implementation Speed | 4 | Requires prospective validation; microbiome-tumor interaction assays not yet standardized |
| Evidence Strength | 5 | Retrospective cohort; NCT number listed suggesting prospective component; abstract only; no effect sizes |
Evidence Maturity Revision: Exploratory (downgraded from "Validated" — authors themselves call for "prospective validation"; the NCT number may refer to the parent cohort, not a validation study).
Article 10 — Hajibandeh et al. — Irreversible electroporation in unresectable LAPC, meta-analysis (PMID 42743900) Meta-analysis (single-arm and comparison), peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | IRE in LAPC has been studied for >10 years; this meta-analysis consolidates data but does not introduce a new concept |
| Clinical Relevance | 7 | Unresectable LAPC is a major unmet need; meta-analysis quantifying OS provides basis for trial design |
| Population Reach | 5 | ~50,000 LAPC patients/year globally who are unresectable |
| Implementation Speed | 5 | IRE is available at specialty centers; meta-analysis may accelerate formal RCT initiation |
| Evidence Strength | 6 | Systematic review/meta-analysis including both single-arm and comparison studies; PRISMA-compliant; random-effects |
Evidence Maturity Revision: Validated (confirmed — meta-analysis of available data; does not reach practice-changing without RCT).
Article 11 — Hoyt-Austin & Schwarz — Lactation as cardiovascular prevention in hypertensive disorders of pregnancy (PMID 42743915) Journal Article/Review, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Lactation-cardiovascular link is not new; framing it as targeted intervention for HDP is a modest reframe |
| Clinical Relevance | 8 | Highly actionable: lactation support is an intervention that can begin immediately postpartum; addresses a modifiable risk factor |
| Population Reach | 8 | Hypertensive disorders of pregnancy affect 10–15% of pregnancies globally; cardiovascular risk reduction is lifelong |
| Implementation Speed | 8 | Lactation support programs exist; no new drug or device needed; could be integrated into existing postpartum care now |
| Evidence Strength | 5 | Review/editorial framing; "RCT inferred" label appears to be a Phase 1 classification artifact; evidence base is observational; abstract only |
Evidence Maturity Revision: Potentially Practice-Changing (confirmed — existing evidence base supports integration into preventive cardiology framework; implementation barriers are behavioral/systemic, not evidentiary).
Article 12 — Elbatreek et al. — eNOS KO + high-fat diet model for HFpEF (PMID 42743759) Murine model study, peer-reviewed, triage score: 8
Species listed as "human" in triage metadata but abstract clearly describes a murine model (eNOS KO mice). This is a non-human study. Clinical Relevance capped at ≤5.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-hit model (genetic + metabolic) for HFpEF in both sexes is a methodologically useful advance for preclinical research |
| Clinical Relevance | 4 | Preclinical model; no human data — capped per rules. High value for researchers, not immediate patient impact |
| Population Reach | 2 | Only relevant to HFpEF researchers currently |
| Implementation Speed | 2 | Model adoption requires lab infrastructure; years from clinical translation |
| Evidence Strength | 5 | Well-designed preclinical study with sex-stratified cohorts; validated against multiple endpoints |
Evidence Maturity Revision: Exploratory (confirmed — preclinical model development).
Article 13 — Gebremariam et al. — HDR brachytherapy radionuclide sources in breast cancer, systematic review (PMID 42744691) Review, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Comparison of Ir-192, Yb-169, Co-60 for HDR brachytherapy; dosimetric comparison is useful but incremental |
| Clinical Relevance | 6 | Directly relevant to radiation oncologists and medical physicists; affects radionuclide selection |
| Population Reach | 7 | Breast cancer is the most common cancer worldwide; HDR brachytherapy is widely used |
| Implementation Speed | 5 | Centers with existing HDR infrastructure could adapt; requires equipment changes for alternative sources |
| Evidence Strength | 4 | Systematic review of dosimetric and clinical studies; quality likely varies; abstract only |
Evidence Maturity Revision: Exploratory (confirmed).
Article 14 — Khan et al. — Patient-level SDoH measure predicts colon cancer outcomes (PMID 42744536) Cohort/Observational, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Patient-level (vs. population-level) SDoH measurement is a meaningful methodological advance; novel tool within an integrated health network |
| Clinical Relevance | 7 | Identifies high-risk patients for directed interventions; directly actionable in cancer care coordination |
| Population Reach | 7 | Colon cancer is the third most common cancer globally; SDoH disparities affect millions |
| Implementation Speed | 6 | Tool is already integrated into one health network; replication requires EHR infrastructure but is feasible |
| Evidence Strength | 5 | Single-institution cohort; no sample size visible; abstract only; selection bias risk |
Equity implications: This article is specifically about equity — identifying patients disadvantaged by social determinants. Those who would benefit most are lower-income, lower-education, and minority populations who currently face worse outcomes. Evidence Maturity Revision: Validated (confirmed within the single network; not yet broadly generalizable).
Article 15 — Villalpando-Gutiérrez et al. — Behavior change techniques for T2DM adherence, systematic review (PMID 42744531) Systematic Review, peer-reviewed, triage score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | BCT for T2DM adherence is a well-established field; synthesis adds value but limited novelty |
| Clinical Relevance | 7 | Medication and lifestyle adherence are major drivers of T2DM outcomes; directly informs clinical and health education practice |
| Population Reach | 9 | T2DM affects ~540 million adults globally; adherence is a near-universal challenge |
| Implementation Speed | 7 | BCT frameworks can be implemented through existing care channels relatively rapidly |
| Evidence Strength | 5 | Systematic review; methodology quality depends on included studies; abstract notes "lack of detailed descriptions" as barrier to replication |
Evidence Maturity Revision: Validated (confirmed as synthesis of existing evidence; not practice-changing in the sense of a new intervention, but practice-informing).
Article 16 — Tzang et al. — Structured exercise and survival in cancer patients, meta-analysis of RCTs (PMID 42744658) Meta-analysis of RCTs, peer-reviewed, triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Survival benefit of structured exercise (not just QoL) is an evolving and genuinely contested claim; this adds RCT-based synthesis |
| Clinical Relevance | 8 | If exercise has a survival benefit beyond QoL, it changes the oncology care model fundamentally |
| Population Reach | 9 | All cancer patients potentially benefit; cancer affects ~20 million people/year globally |
| Implementation Speed | 8 | Exercise programs require no regulatory approval; could be implemented in cancer centers immediately if evidence is accepted |
| Evidence Strength | 7 | Meta-analysis of RCTs (PROSPERO registered); strongest design short of a single mega-trial; but abstract only, heterogeneity unknown |
Key quantitative result: Not visible in abstract, but claims "survival and recurrence benefits." Main limitation: Heterogeneity across cancer types and exercise modalities; abstract only; effect sizes unknown. Equity implications: Structured exercise programs require access, transportation, and physical capacity — underserved and elderly populations may face barriers. Evidence Maturity Revision: Potentially Practice-Changing (upgraded from abstract's implied status — PROSPERO-registered meta-analysis of RCTs addressing survival in oncology is a high-value finding).
Article 17 — Shulman et al. — ctDNA risk classification in Ewing sarcoma (COG/LEOPARD) (PMID 42743455) Prospective cohort, JCO, peer-reviewed, triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Prospective validation of ctDNA-based risk classification in Ewing sarcoma; integration with clinical-molecular features for three-tier risk group is genuinely novel |
| Clinical Relevance | 8 | Published in JCO from COG — high credibility; risk classification directly informs treatment intensity decisions in a pediatric cancer |
| Population Reach | 4 | Ewing sarcoma: ~1,000 new cases/year in US; relative to the relevant population (children with ES), reach is high |
| Implementation Speed | 6 | ctDNA assays are available; integration into COG protocols is feasible within 2–5 years |
| Evidence Strength | 7 | Prospective observational cohort from two cooperative group studies; multicenter; pediatric oncology gold standard design |
Key quantitative result: ctDNA burden + clinical-molecular features differentiate low/intermediate/high-risk groups (specific thresholds not available from abstract). External validation: Multi-institutional (COG + LEOPARD); prospective design. Main limitation: Observational (not interventional); abstract only; whether risk stratification changes outcomes depends on subsequent therapeutic adaptation. Equity implications: Pediatric cancers in lower-income countries have very limited access to ctDNA testing; this could widen diagnostic disparities globally. Evidence Maturity Revision: Validated (confirmed — prospective multicenter cohort).
Article 18 — Zou et al. — ctDNA + CA19-9 longitudinal monitoring in resected PDAC (PMID 42743887) Prospective cohort (interim), peer-reviewed, triage score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Dual-biomarker longitudinal framework (ctDNA + CA19-9) across multiple postoperative windows in resected PDAC is a clinically refined approach |
| Clinical Relevance | 7 | Postoperative relapse detection in PDAC is an area of extreme unmet need; this framework is practical and could change surveillance protocols |
| Population Reach | 5 | Resected PDAC: ~15–20% of all PDAC patients; overall PDAC burden ~500,000/year |
| Implementation Speed | 6 | Both biomarkers are clinically accessible; dual monitoring protocol could be implemented in specialized centers |
| Evidence Strength | 6 | Prospective cohort, n=136, multicenter feel from authors; interim analysis limits conclusions; abstract only |
Evidence Maturity Revision: Validated (confirmed — prospective cohort with defined endpoints).
Article 19 — Dienstmann et al. — ctDNA genomic profiling in HR+/HER2- metastatic breast cancer (PMID 42743769) Cohort/Observational, peer-reviewed, triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Prospective real-world ESR1 mutation prevalence data across treatment lines; confirms guideline-endorsed approach with real-world data |
| Clinical Relevance | 8 | ESR1 mutations directly guide eligibility for elacestrant and other endocrine agents; plasma NGS results immediately change prescribing |
| Population Reach | 8 | HR+/HER2- mBC is the most common metastatic breast cancer subtype; ~700,000 patients in US/EU |
| Implementation Speed | 7 | Plasma NGS is guideline-endorsed; results support wider adoption of liquid biopsy in routine practice |
| Evidence Strength | 6 | Real-world prospective cohort; large author consortium suggests multicenter; abstract only; no sample size or mutation rates visible |
Evidence Maturity Revision: Validated (confirmed — real-world prospective data supporting existing guidelines).
Article 20 — Hooper et al. — Aggressive cytotoxic lymphomas of the auricle (PMID 42743998) Journal Article (unspecified), peer-reviewed, triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Distinguishing auricle lymphomas by behavior (indolent vs. aggressive) with a clinicopathologic series is genuinely novel for a rare presentation |
| Clinical Relevance | 6 | Clinically important for dermatopathologists and hematologists — recognition could prevent delayed diagnosis |
| Population Reach | 2 | Extremely rare presentation |
| Implementation Speed | 5 | Increased awareness translates to practice immediately; no new intervention needed |
| Evidence Strength | 3 | Unspecified design (likely case series); abstract only |
Evidence Maturity Revision: Exploratory (confirmed).
Article 21 — Chiu et al. — Liraglutide in adolescent obesity, Taiwan multicenter real-world (PMID 42744726) Cohort/Observational, peer-reviewed, triage score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world pediatric GLP-1 data from Asia adds to a growing but still thin evidence base for adolescent use |
| Clinical Relevance | 7 | Pediatric obesity is a significant and underserved therapeutic area; real-world safety/efficacy data directly inform practice |
| Population Reach | 8 | Adolescent obesity is a global epidemic; GLP-1 RAs are increasingly prescribed in this group |
| Implementation Speed | 7 | Liraglutide is already approved in adolescents (FDA, EMA); this adds real-world confidence |
| Evidence Strength | 5 | Multicenter but observational; no comparator; abstract only; sample size unknown |
Evidence Maturity Revision: Validated (confirmed — real-world evidence supporting existing approvals).
Selected additional articles scored more briefly (triage 6–7, peer-reviewed, human):
Article 22 — Naghshi et al. — Whole-grain consumption and cardiometabolic risk, meta-analysis of RCTs (PMID 42743912)
Triage metadata labels species as "animal" — the abstract describes a meta-analysis of human RCTs. This is a triage metadata error. Rescoring accordingly.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Whole grain-cardiometabolic link is well-established; this adds RCT-level quantification |
| Clinical Relevance | 7 | Published in Eur Heart J; population-level dietary guidance with direct clinical relevance |
| Population Reach | 10 | Cardiometabolic disease is the leading cause of global mortality |
| Implementation Speed | 9 | Dietary guidance is immediately implementable; no regulatory hurdle |
| Evidence Strength | 7 | Meta-analysis of RCTs in a top cardiology journal; strongest dietary intervention evidence design |
Evidence Maturity Revision: Potentially Practice-Changing (upgrading — Eur Heart J meta-analysis of RCTs on a modifiable behavior affecting global mortality).
Article 23 — Serikawa et al. — Cumulative LDL-C exposure after ACS (PMID 42744018)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Estimated cumulative LDL-C (eCLE) as a simple practical metric is incremental |
| Clinical Relevance | 6 | ACS secondary prevention is a major clinical domain; eCLE may aid risk stratification |
| Population Reach | 8 | ACS affects millions globally; secondary prevention is universal |
| Implementation Speed | 7 | Simple calculable metric; no new test needed |
| Evidence Strength | 6 | RCT-derived dataset (inferred); note that eCLE did not improve discrimination beyond age+LDL separately |
Evidence Maturity Revision: Validated (confirmed; negative/incremental finding is still valid).
Remaining articles (triage score ≤6 or out of scope): Scored summarily; detailed analysis would not change top-ranking results. Key observations:
- PMID 42742817 (Robotic THA): Out of scope for watchlist; excluded from ranking.
- PMID 42743353 (Census-based adolescent depression): Mixed species, exploratory; low clinical relevance.
- PMID 42744691 (Breast HDR brachytherapy): Relevant but review-level evidence.
- PMID 42744572 (US primary care access gap): Health equity relevance; important but low evidence strength.
- PMID 42743886 (cfbDNA in PDAC): High novelty, scored above.
- PMID 42742480 (CJD perspective): Intellectually interesting; no treatment available; Exploratory.
- PMID 42744658 (Exercise + cancer survival): Scored above — ranks high.